Latest Amides Stories
SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc.
Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, notes that Xarelto® is surpassing Pradaxa® in the number of reported adverse events, according to the Institute for Safe
-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival
SAN ANTONIO, June 30, 2014 /PRNewswire/ -- GenSpera, Inc.
Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.
RIDGEFIELD, Conn., June 20, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today the initiation of a new international study of Pradaxa® (dabigatran etexilate mesylate).
German drugmaker Boehringer Ingelheim has offered to settle almost 4,000 Pradaxa lawsuits in the United States.
New research study “Antibiotics Partnering Terms and Agreements” worked out by CurrentPartnering is now available at MarketPublishers.com. London, UK (PRWEB)
A recent settlement announcement involving Pradaxa has been announced by the manufacture, Boehringer Ingelheim. Toledo, Ohio (PRWEB) June 05, 2014 Boehringer
- totally perplexed and mixed up.